[en] In a double-blind, placebo-controlled study, 109 patients suffering from local and vasomotor postmenopausal complaints were randomly assigned to treatment with either depot vaginal suppositories containing 3.5 mg oestriol (E3) or a placebo. The treatment schedule comprised one vaginal suppository twice weekly for 3 weeks initially, followed by maintenance therapy with one vaginal suppository weekly for the 6-month study period. The effectiveness of the therapy was assessed on the basis of questionnaires (Kupperman index for vasomotor complaints and an original urogenital index for local complaints) and gynaecological examinations which included assessments of vaginal cytology, vaginal pH and Doderlein bacilli. To rule out induced endometrial proliferation, endometrial biopsies were performed in 50 women before and after the study. The vaginal depot (E3) formulation showed highly significant superiority over the placebo with respect to therapeutic effect on local urogenital complaints and alleviation of vasomotor complaints, including hot flushes. Analysis of the endometrial biopsies indicated that the monotherapy used caused no endometrial stimulation. Taking into account the minimal rate of adverse effects, the 3.5 mg E3 depot formulation studied represents a useful variant in the range of preparations available for the treatment of post-menopausal complaints.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Vervliet, J.
Buytaert, Ph
Language :
English
Title :
Efficacy of Sustained-Release Vaginal Oestriol in Alleviating Urogenital and Systemic Climacteric Complaints
Publication date :
June 1991
Journal title :
Maturitas
ISSN :
0378-5122
eISSN :
1873-4111
Publisher :
Elsevier North Holland Biomedical Press, Limerick, Ireland
Birkhäuser, Huber, Mall-Haefeli (1986) Absorption, tolerance and clinical effect of sustained release vaginal formulation of estriol. Arch Gynaecol 239:228-231.
Versi (1986) The bladder in the menopausal woman. A modern approach to the perimenopausal years , RB Greenblatt, New Developments in Biosciences 2, Walter de Gruyter, Berlin, New York; 93-102.
Wenderlein (1986) Psychosocial aspects in the perimenopause. A modern approach to the perimenopausal years , RB Greenblatt, New Developments in Biosciences 2, Walter de Gruyter, Berlin, New York; 87-92.
Kupperman, Blatt, Wiesbader, Filler (1953) Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 13:688-703.
Whitehead, Padwick, Endacott, Pryse-Davies (1985) The effect of transdermal oestradiol on the endometrium of post- menopausal women. Am J Obstet Gynecol 152:1079-1084.
Sachs Angewandte statistik , Springer Verlag, Berlin; 1984, 522.
Fink, Collins, Papadaki, O'Reilly, Ginsburg (1985) Vaginal estriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol 1:1-2.
Wesel, Etienne, Lestienne (1981) Clinical cytological and biological study of the intra-vaginal administation of oestriol (Ortho-Gynest) in post-menopausal patients. Maturitas 3:271-277.
Michalas, Papandrikos, Koutselini, Tzinqoumis (1980) Local therapy of atrophic vaginal conditions with oestriol suppositories. J Int Med Res 8:358-360.
Lauritzen (1973) The management of the pre-menopausal and the post-menopausal patient. Ageing and estrogens , PA van Keep, C Lauritzen, Frontiers of hormone research, Karger, Basel; 2:2-21.
Ginsburg, O'Reilly, Fink, Collins, Weiss (1987) Hormonal effects of a new sustained release vaginal estriol pessary. J Gynaecol Endocrinol 3:1-4.